We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (383)
- Scheduling (national classification system) (164)
- Safety monitoring and information (26)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Medicinal cannabis hub (6)
- Clinical trials (5)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
758 result(s) found, displaying 426 to 450
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 9 July 2020
-
Meeting statementsCommunique from the meeting of the TGACC
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 19 March 2020
-
Scheduling decisions (final)NCEs to be included in the June 2020 Poisons Standard
-
-
Scheduling submissionsPublic submissions on matters referred to the November 2019 scheduling meetings, and received during the interim consultation period
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Scheduling decisions (final)Public notice of the Delegates' final decisions to amend the Poisons Standard
-
Corporate reportsStatistical information for 1 July to 31 December 2019 in relation to our regulation of therapeutic goods
-
Corporate reportsIn 2019, the TGA conducted 10 pharmacovigilance inspections of Australian medicine sponsors
-
Meeting statementsThe TGACC meeting was held on 20 Feb 2020, a communique has been published
-
Scheduling decisions (final)Poisons Standard amendments to hydroxychloroquine to ensure continued availability during the COVID-19 pandemic
-
Scheduling decisions (final)Amendments in relation to hydroxychloroquine and salbutamol
-
TGA laboratory testing reportsUpdates have been made to the previously published report related to the testing of HPV vaccines available in Australia
-
Corporate reportsThis report describes the first 12 months of the mandatory reporting scheme
-
Corporate reportsThe TGA thanks respondents who provided a submission in response to the public consultation paper
-
Meeting statementsThe Advisory Committee on Biologicals (ACB) is a statutory advisory committee established by the Therapeutic Goods Regulations 1990
-
Meeting statementsThe Advisory Committee on Biologicals (ACB) is a statutory advisory committee established by the Therapeutic Goods Regulations 1990.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 5 March 2020
-
Corporate reportsThe Health Products Regulation Group has published a new regulatory science strategy
-
Corporate reportsOur plan for how HPRG will maintain and build its regulatory science capability over the next 5 years
-
Scheduling decisions (final)Final decision in relation to risankizumab
-
Scheduling decisions (final)Recommendations for the scheduling of New Chemical Entities for inclusion in the Poisons Standard
-
TGA laboratory testing reportsThe TGA Laboratories has published a detailed report related to the testing of measles vaccines available in Australia